S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.47 (+0.41%)
AAPL   175.29 (+2.40%)
MSFT   334.95 (+0.01%)
FB   330.83 (+2.48%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,517.60 (-0.16%)
TSLA   1,066.08 (+1.36%)
NVDA   317.90 (-1.96%)
BABA   125.18 (-0.29%)
NIO   35.05 (+5.83%)
CGC   10.93 (+2.73%)
AMD   144.97 (+0.08%)
GE   98.46 (+0.93%)
MU   85.81 (-0.02%)
T   23.16 (+0.35%)
F   19.83 (-0.65%)
DIS   153.39 (+1.71%)
PFE   51.43 (-0.56%)
AMC   32.08 (+3.35%)
ACB   6.59 (+3.29%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.47 (+0.41%)
AAPL   175.29 (+2.40%)
MSFT   334.95 (+0.01%)
FB   330.83 (+2.48%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,517.60 (-0.16%)
TSLA   1,066.08 (+1.36%)
NVDA   317.90 (-1.96%)
BABA   125.18 (-0.29%)
NIO   35.05 (+5.83%)
CGC   10.93 (+2.73%)
AMD   144.97 (+0.08%)
GE   98.46 (+0.93%)
MU   85.81 (-0.02%)
T   23.16 (+0.35%)
F   19.83 (-0.65%)
DIS   153.39 (+1.71%)
PFE   51.43 (-0.56%)
AMC   32.08 (+3.35%)
ACB   6.59 (+3.29%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.47 (+0.41%)
AAPL   175.29 (+2.40%)
MSFT   334.95 (+0.01%)
FB   330.83 (+2.48%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,517.60 (-0.16%)
TSLA   1,066.08 (+1.36%)
NVDA   317.90 (-1.96%)
BABA   125.18 (-0.29%)
NIO   35.05 (+5.83%)
CGC   10.93 (+2.73%)
AMD   144.97 (+0.08%)
GE   98.46 (+0.93%)
MU   85.81 (-0.02%)
T   23.16 (+0.35%)
F   19.83 (-0.65%)
DIS   153.39 (+1.71%)
PFE   51.43 (-0.56%)
AMC   32.08 (+3.35%)
ACB   6.59 (+3.29%)
BA   211.04 (+1.06%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.47 (+0.41%)
AAPL   175.29 (+2.40%)
MSFT   334.95 (+0.01%)
FB   330.83 (+2.48%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,517.60 (-0.16%)
TSLA   1,066.08 (+1.36%)
NVDA   317.90 (-1.96%)
BABA   125.18 (-0.29%)
NIO   35.05 (+5.83%)
CGC   10.93 (+2.73%)
AMD   144.97 (+0.08%)
GE   98.46 (+0.93%)
MU   85.81 (-0.02%)
T   23.16 (+0.35%)
F   19.83 (-0.65%)
DIS   153.39 (+1.71%)
PFE   51.43 (-0.56%)
AMC   32.08 (+3.35%)
ACB   6.59 (+3.29%)
BA   211.04 (+1.06%)
NASDAQ:ATHX

Athersys Stock Forecast, Price & News

$1.10
+0.03 (+2.80%)
(As of 12/8/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.07
$1.14
50-Day Range
$1.01
$1.40
52-Week Range
$0.92
$3.03
Volume
128,579 shs
Average Volume
2.14 million shs
Market Capitalization
$258.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.56
30 days | 90 days | 365 days | Advanced Chart
Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.


Athersys logo

About Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Headlines

Athersys, Inc. (NASDAQ:ATHX) Short Interest Update
November 20, 2021 |  americanbankingnews.com
Athersys, Inc. (NASDAQ:ATHX) Director Buys $81,600.00 in Stock
November 19, 2021 |  americanbankingnews.com
Bank of America Lowers Athersys (NASDAQ:ATHX) to Neutral
November 19, 2021 |  americanbankingnews.com
Athersys, Inc. (NASDAQ:ATHX) CFO Ivor Macleod Buys 15,000 Shares
November 17, 2021 |  americanbankingnews.com
Athersys (NASDAQ:ATHX) Issues Earnings Results
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
97
Year Founded
1995

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$0.12 per share

Profitability

Net Income
$-78.76 million
Pretax Margin
-1,442.59%

Debt

Price-To-Earnings

Miscellaneous

Free Float
210,535,000
Market Cap
$258.76 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

Social Links


MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

703rd out of 1,394 stocks

Pharmaceutical Preparations Industry

337th out of 674 stocks

Analyst Opinion: 2.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athersys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares.
View analyst ratings for Athersys
or view top-rated stocks.

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 14.1% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Athersys?

Athersys saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is currently 13.2 days. Currently, 7.9% of the company's shares are sold short.
View Athersys' Short Interest
.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Athersys
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.01. During the same period last year, the firm earned ($0.11) earnings per share.
View Athersys' earnings history
.

What price target have analysts set for ATHX?

1 Wall Street analysts have issued 1 year price targets for Athersys' shares. Their forecasts range from $1.25 to $1.25. On average, they anticipate Athersys' stock price to reach $1.25 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for Athersys
or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Athersys own?

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.41%), Geode Capital Management LLC (1.63%), Jacob Asset Management of New York LLC (0.36%), Bank of New York Mellon Corp (0.30%), Millennium Management LLC (0.26%) and UBS Group AG (0.21%). Company insiders that own Athersys stock include Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys
.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., Livingston Group Asset Management CO operating as Southport Capital Management, NEXT Financial Group Inc, Morgan Stanley, UBS Group AG, Cedar Brook Financial Partners LLC, and Jane Street Group LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys
or view top insider-selling stocks.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Geode Capital Management LLC, BlackRock Inc., Citadel Advisors LLC, Jacob Asset Management of New York LLC, SG Americas Securities LLC, Metropolitan Life Insurance Co NY, and Cerity Partners LLC. Company insiders that have bought Athersys stock in the last two years include Ismail Kola, Ivor Macleod, and Kenneth H Traub.
View insider buying and selling activity for Athersys
or or view top insider-buying stocks.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.10.

How much money does Athersys make?

Athersys has a market capitalization of $258.76 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at [email protected], or via fax at 216-361-9495.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.